ACB

NASDAQ | TSX: ACB Revised Hostile Bid continues to significantly undervalue Aurora; fails to address concerns previously raised by the Board.  Aurora's Special Committee is actively exploring strategic alternatives to maximize value for Aurora shareholders.

A Q1 FY2027 revenue record from Tilray Brands (NASDAQ:TLRY) is drawing heavy selling, because the segment that built the company's following moved the wrong way. Tilray Brands shares are at $3.

NASDAQ | TSX: ACB Multi-million-dollar investment results in increased domestic production capacity in Germany, more than doubling expected annual flower output. Enhanced facility adopts Aurora's proven cultivation practices and proprietary genetics to support consistent, high-quality production.

Aurora's Special Committee will commence a thorough and independent review of the revised Hostile Bid and the Board will provide a formal recommendation to shareholders once the review is complete.   Shareholders are advised to TAKE NO ACTION pending a formal recommendation.

The multi-year cannabis sector bear market is starting to give way to a calculated wave of industry consolidation. Behind the urge to merge is a significant shift in U.S. federal regulatory policy, encouraging better-capitalized operators to secure global supply chains before tax relief drives widespread multiple expansion.

Curaleaf Hldgs Inc. (OTCQX:CURLF), the Connecticut-based cannabis company, has raised its offer for Aurora Cannabis Inc (TSX:ACB, NASDAQ:ACB), a Canadian cannabis producer, by 25% to a total implied value of $5 per Aurora share in cash and stock. The new price is 86% above Aurora's 30-day volume-weighted average share price of $2.75 as of August 10, the day before Curaleaf announced its intention to make its initial offer.

NASDAQ| TSX: ACB Re-affirms FY27 Q2 guidance for sequential growth in quarterly net revenue and adjusted EBITDA 1 Following the receipt of EU-GMP certification in July, Safari Flower Company is expected to contribute incremental net revenue and adjusted EBITDA 1   Continued strong performance in Germany and Poland, contributing to profitable international growth expectations and leadership positions in the two largest EU markets, including #1 market share by revenue in Poland UK market expansion underway, with recently announced acquisition of Internode Pharma and HAP Pharma Limited expected to support further market share growth EDMONTON, AB, Sept. 16, 2026 /PRNewswire/ -- Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NASDAQ: ACB), the leading Canadian-based global medical cannabis company, today provided a business update, highlighting the expected additional benefits of the Safari Flower Company acquisition, continued strong performance in key high margin international markets, and reaffirmed its fiscal year 2027 Q2 guidance.

Cross-border consolidation in the cannabis industry has moved from executive speculation into aggressive dealmaking. As regulatory hurdles begin to clear across North America and Europe, operators are moving quickly to strengthen their finances and expand globally.

NASDAQ | TSX: ACB Curaleaf's announcement is a desperate effort to shift attention away from the fundamental issue facing shareholders: its inadequate hostile bid undervalues Aurora. Curaleaf's attempt to fabricate issues ignores the reality of its own balance sheet: more than $1 billion of debt1, including $500 million carrying an 11.5% interest rate, exposing shareholders to significant financial and dilution risks.

Options-income ETFs now offer monthly payouts that dwarf what traditional dividend stocks provide, but before you move a dollar, there are tax mechanics and capital preservation risks that most income investors completely overlook.